Clinical Trials Browser

Phase 3 × Neoplasms × trastuzumab deruxtecan × Clear all

NCT07022483 2026-05-28

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms